KAKKIS EMIL D (President & CEO) received a stock award from ULTRAGENYX PHARMACEUTICAL INC.

Compensation award — not an open‑market transaction. Less informative as a directional signal.

A · 2 awards

KAKKIS EMIL D

Filed: 3/5/2024ACC: 0000950170-24-026625

InsiderKAKKIS EMIL DCIK 1248093

→

IssuerULTRAGENYX PHARMACEUTICAL INC.CIK 1515673

DirectorOfficer· President & CEO

Since Mar 2026

+94.24K

Net shares

Net buyer

$935.1K

Total sold

Open market trades

0B · 0S

Total transactions

111.65K acquired · 17.42K disposed

Non-Derivative Transactions3

Common Stock

Direct

A · Award

+38.43K

Price / share

—

Trade value

—

% of position

7.1%

3/1/2024

539.77K→578.20K

Common Stock

Direct

F · Tax Withholding

−17.42K

Price / share

$53.69

Trade value

$935.12K

% of position

3.0%

3/1/2024

578.20K→560.78K

Common Stock

Direct

A · Award

+3.13K

Price / share

—

Trade value

—

% of position

0.6%

3/1/2024

560.78K→563.91K

Total

Net shares

+24.14K

Net value

-$935.12K

Security	Date	Type	Shares	Price / Share	Trade Value	% of Position	Held Before	Held After
Common Stock Direct	3/1/2024	A · Award	+38.43K	—	—	7.1%	539.77K	578.20K
Common Stock Direct	3/1/2024	F · Tax Withholding	−17.42K	$53.69	$935.12K	3.0%	578.20K	560.78K
Common Stock Direct	3/1/2024	A · Award	+3.13K	—	—	0.6%	560.78K	563.91K
Total			+24.14K		-$935.12K

Derivative Transactions1

Stock Option (Right to Buy)

Direct

A · Award

Converts to

Common Stock

70.09K shares

+70.09K

Strike price

53.69

Held after

70.09K

Exercisable

—

3/1/2024

Security	Converts To	Date	Type	Shares	Strike Price	Exercisable	Held After
Stock Option (Right to Buy) Direct	Common Stock70.09K shares	3/1/2024	A · Award	+70.09K	53.69	—	70.09K

Non-Derivative Holdings (Post-Transaction)1

Common Stock

Indirect

Shares owned2.26M

Total

2.26M indirect2.26M

Security Title	Shares Owned	Ownership Type
Common Stock	2.26M	Indirect
Total	2.26M	2.26M indirect

Derivative Holdings (Post-Transaction)0

No derivative holdings reported